AUR-110 / Dr. Reddy’s - LARVOL DELTA

Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025 (Businesswire) - "SMARCA2 and SMARCA4 regulate chromatin architecture by mobilizing and repositioning nucleosomes on DNA, which is critical for various genomic functions, including transcriptional regulation, DNA recombination and repair, and mitotic chromosome segregation...Additionally, with the use of Aurigene’s proprietary long-acting injectable (LAI) formulation, AUR110, a candidate with US-FDA clearance for first-in-human studies, has shown potent and comparable anti-tumor activity following once every three week intravenous dosing."

Preclinical • Solid Tumor